Angiogenesis: Advances in Basic Science and Therapeutic Applications

血管生成：基础科学和治疗应用的进展

• 批准号: 8205061
• 负责人: James Wavell Aiken
• 金额: $ 1.8万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-04 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8205061
• 关键词: Address; Age related macular degeneration; Angiogenesis Inhibitors; Area; Basic Science; Biological; Blood Vessels; Cardiovascular Diseases; Cells; Clinical; Clinical Trials; Collaborations; Development; Developmental Biology; Diagnostic; Discipline; Disease; Endothelial Cells; FDA approved; Fostering; Genetic; Health; Inflammation; Knowledge; Malignant Neoplasms; Metabolism; MicroRNAs; Molecular; Outcome; Pathologic Neovascularization; Patients; Postdoctoral Fellow; Process; Regulation; Request for Proposals; Research; Research Personnel; Resistance; Role; Signal Pathway; Signal Transduction; Stem cells; Stromal Cells; Students; Therapeutic; Thinking; Tissue Engineering; Tissues; Training; Utah; Work; angiogenesis; base; cancer therapy; cell type; improved; interest; meetings; neovascular; nervous system disorder; new therapeutic target; ocular angiogenesis; symposium; therapeutic angiogenesis; tool; tumor

DESCRIPTION (provided by applicant): This proposal requests support for a Keystone Symposia meeting entitled Angiogenesis: Advances in Basic Science and Therapeutic Applications, organized by Napoleone Ferrara, Anne C. Eichmann and Kenneth Walsh, which will be held in Snowbird, Utah from January 16 - 21, 2012. Much progress has been made in the identification of key signaling pathways regulating blood vessel development. There is also evidence that various stromal cell types participate in normal and pathological angiogenesis in a tissue- or context-specific fashion. However, many important molecular and biological questions regarding these processes remain unanswered. In addition, several angiogenesis inhibitors have been approved by the FDA as therapy for cancer or intraocular neovascular disorders. Perhaps some of the most successful applications of anti- angiogenic therapy are in age-related macular degeneration and other intraocular neovascular diseases, although such findings have been rarely presented outside specialized meetings. The Keystone Symposia meeting on Angiogenesis: Advances in Basic Science and Therapeutic Applications will critically examine the latest basic science on the regulation of angiogenesis in health and disease; discuss the lessons from clinical trials in cancer and intraocular neovascular disorders; and identify novel therapeutic targets. In addition, a renewed interest in therapeutic angiogenesis by tissue-engineering or stem cell-based approaches will be discussed.

描述（由申请人提供）： 该提案请求支持由 Napoleone Ferrara、Anne C. Eichmann 和 Kenneth Walsh 组织的题为“血管生成：基础科学和治疗应用的进展”的 Keystone 研讨会，该会议将于 2012 年 1 月 16 日至 21 日在犹他州斯诺伯德举行。在识别调节血管发育的关键信号通路方面已取得了很大进展。还有证据表明，各种基质细胞类型以组织或环境特异性的方式参与正常和病理性血管生成。然而，有关这些过程的许多重要的分子和生物学问题仍未得到解答。此外，几种血管生成抑制剂已被 FDA 批准用于治疗癌症或眼内新生血管疾病。也许抗血管生成疗法的一些最成功的应用是在年龄相关性黄斑变性和其他眼内新生血管疾病中，尽管这些发现很少在专门会议之外提出。血管生成专题研讨会：基础科学和治疗应用的进展将批判性地研究健康和疾病中血管生成调节的最新基础科学；讨论癌症和眼内新生血管疾病临床试验的经验教训；并确定新的治疗靶点。此外，还将讨论通过组织工程或基于干细胞的方法对治疗性血管生成重新产生的兴趣。